Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU/intubation/death 44% Improvement Relative Risk Hospitalization 37% c19early.org/mf Yeh et al. NCT02788903 Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland
Yeh et al., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2022-002774, NCT02788903 (history)
Yeh et al., Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five.., BMJ Open Diabetes Research & Care, doi:10.1136/bmjdrc-2022-002774, NCT02788903
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 4,944 COVID-19 patients with type 2 diabetes in the USA, showing lower risk of hospitalization and combined ICU/intubation/death with metformin use.
ICU/intubation/death, 44.0% lower, OR 0.56, p < 0.001, RR approximated with OR.
risk of hospitalization, 37.0% lower, OR 0.63, p < 0.001, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yeh et al., 9 Jun 2022, retrospective, USA, peer-reviewed, mean age 62.3, 9 authors, study period 1 March, 2020 - 28 February, 2021, trial NCT02788903 (history).
Contact: hyeh1@jhmi.e.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Original research Hospitalization and mortality in patients with COVID-­19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland Hsin-­Chieh Yeh ‍ ‍,1 Jennifer L Kraschnewski,2,3 Lan Kong,3 Erik B Lehman,3 Emily S Heilbrunn,2 Pamela Williams,4 Jennifer M Poger,2 Erica Francis,2 Cindy L Bryce5 To cite: Yeh H-­C, Kraschnewski JL, Kong L, et al. Hospitalization and mortality in patients with COVID-­19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland. BMJ Open Diab Res Care 2022;10:e002774. doi:10.1136/ bmjdrc-2022-002774 ► Additional supplemental material is published online only. To view, please visit the journal online (http://d​ x.​doi.​ org/​10.​1136/b​ mjdrc-​2022-​ 002774). Received 18 January 2022 Accepted 16 May 2022 © Author(s) (or their employer(s)) 2022. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. For numbered affiliations see end of article. Correspondence to Hsin-­Chieh Yeh; ​hyeh1@​jhmi.e​ du ABSTRACT Objective To identify the demographic and clinical characteristics associated with adverse COVID-­19 outcomes across a 12-­month period in 2020 and 2021. Research design and methods We conducted a retrospective cohort study using electronic health records from five academic health systems in Pennsylvania and Maryland, including patients with COVID-­19 with type 2 diabetes or at risk of type 2 diabetes. Patients were classified based on 30-­day outcomes: (1) no hospitalization; (2) hospitalization only; or (3) a composite measure including admission to the intensive care unit (ICU), intubation, or death. Analyses were conducted in patients with type 2 diabetes and patients at risk of type 2 diabetes separately. Results We included 15 725 patients with COVID-­19 diagnoses between March 2020 and February 2021. Older age and higher Charlson Comorbidity Index scores were associated with higher odds of adverse outcomes, while COVID-­19 diagnoses later in the study period were associated with lower odds of severe outcomes. In patients with type 2 diabetes, individuals on insulin treatment had higher odds for ICU/intubation/death (OR=1.59, 95% CI 1.27 to 1.99), whereas those on metformin had lower odds (OR=0.56, 95% CI 0.45 to 0.71). Compared with non-­Hispanic White patients, Hispanic patients had higher odds of hospitalization in patients with type 2 diabetes (OR=1.73, 95% CI 1.36 to 2.19) or at risk of type 2 diabetes (OR=1.77, 95% CI 1.43 to 2.18.) Conclusions Adults who were older, in racial minority groups, had multiple chronic conditions or were on insulin treatment had higher risks for severe COVID-­19 outcomes. This study reinforced the urgency of preventing COVID-­19 and its complications in vulnerable populations. Trial registration number NCT02788903.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit